These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 36745342

  • 1. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
    Neuzillet C, Artru P, Assenat E, Edeline J, Adhoute X, Sabourin JC, Turpin A, Coriat R, Malka D.
    Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
    [Abstract] [Full Text] [Related]

  • 2. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN.
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [Abstract] [Full Text] [Related]

  • 3. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M, Heumann T, Goff L, Agarwal R.
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [Abstract] [Full Text] [Related]

  • 4. How I treat biliary tract cancer.
    Lamarca A, Edeline J, Goyal L.
    ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
    [Abstract] [Full Text] [Related]

  • 5. [Not Available].
    Valéry M, Cervantes B, Smolenschi C, Boige V, Ducreux M, Cohen R, Hollebecque A.
    Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
    [Abstract] [Full Text] [Related]

  • 6. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M.
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [Abstract] [Full Text] [Related]

  • 7. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M.
    Clin Cancer Res; 2023 Dec 01; 29(23):4853-4862. PubMed ID: 37773629
    [Abstract] [Full Text] [Related]

  • 8. Cell of origin in biliary tract cancers and clinical implications.
    Moeini A, Haber PK, Sia D.
    JHEP Rep; 2021 Apr 01; 3(2):100226. PubMed ID: 33665585
    [Abstract] [Full Text] [Related]

  • 9. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 10. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F.
    Front Immunol; 2022 Feb 15; 13():946861. PubMed ID: 35967452
    [Abstract] [Full Text] [Related]

  • 11. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, Lau D, Lesinski GB, Yarchoan M.
    JCO Precis Oncol; 2022 Jun 15; 6():e2100510. PubMed ID: 35675577
    [Abstract] [Full Text] [Related]

  • 12. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE, Masood A, Shroff RT.
    Lancet Gastroenterol Hepatol; 2021 Nov 15; 6(11):956-969. PubMed ID: 34626563
    [Abstract] [Full Text] [Related]

  • 13. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L.
    Front Biosci (Landmark Ed); 2022 Jun 08; 27(6):185. PubMed ID: 35748261
    [Abstract] [Full Text] [Related]

  • 14. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Uson Junior PLS, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L.
    Ann Oncol; 2022 Dec 08; 33(12):1269-1283. PubMed ID: 36089135
    [Abstract] [Full Text] [Related]

  • 15. Advances in immunotherapy for biliary tract cancers.
    Zhao Y, Yang M, Feng J, Wang X, Liu Y.
    Chin Med J (Engl); 2024 Mar 05; 137(5):524-532. PubMed ID: 37646139
    [Abstract] [Full Text] [Related]

  • 16. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    Merters J, Lamarca A.
    J Hepatol; 2023 Mar 05; 78(3):652-657. PubMed ID: 36400328
    [Abstract] [Full Text] [Related]

  • 17. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
    Mayr C, Kiesslich T, Modest DP, Stintzing S, Ocker M, Neureiter D.
    Expert Opin Investig Drugs; 2022 Feb 05; 31(2):221-233. PubMed ID: 35098846
    [Abstract] [Full Text] [Related]

  • 18. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
    Lamarca A, Barriuso J, McNamara MG, Valle JW.
    J Hepatol; 2020 Jul 05; 73(1):170-185. PubMed ID: 32171892
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY.
    Eur J Cancer; 2019 Oct 05; 120():31-39. PubMed ID: 31476489
    [Abstract] [Full Text] [Related]

  • 20. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
    Iyer P, Chen MH, Goyal L, Denlinger CS.
    Chin Clin Oncol; 2020 Feb 05; 9(1):7. PubMed ID: 32146818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.